Binggrae Reports 10.7% Increase in 3Q Operating Profit… "Cost Cuts and Strong Overseas Performance"
Profitability Improves Despite a 4.8% Decline in Revenue to 456.3 Billion Won
Overseas Sales Rise 17.7% Amid Sluggish Domestic Demand, Signaling a 'Growth Trend'
Profit-Focused Management, Including Cost Reduction and Management of Low-Profit Products
[E-Daily Reporter kim mi-kyung ] Binggrae continued its growth momentum in the third quarter of this year, despite a decline in sales due to sluggish domestic demand, thanks to strong overseas operations and cost-cutting measures.
Binggrae(005180)The company announced on the 16th that its consolidated operating profit for the third quarter of this year totaled 65.2 billion won. This represents a 10.7% increase compared to the same period last year. Revenue for the same period fell 4.8% to 456.3 billion won.
In the domestic market, sales of refrigerated products declined due to sluggish consumer spending. Sales of frozen products also decreased due to a base effect resulting from strong performance in the same period last year. However, operating profit increased thanks to growth in overseas operations and strengthened profitability-focused management activities, including cost-cutting measures.
A Binggrae official explained, “Our overseas business continued its robust growth trend, rising 17.7% year-over-year in key markets such as the U.S., China, and Vietnam.” The official added, “Despite the decline in revenue, operating profit increased thanks to strengthened profitability-focused management activities, including ongoing cost-cutting measures, management of low-margin products, and optimization of selling, general, and administrative expenses.”
LG Energy Solution delivered encouragement gifts to the children of its employees ahead of the 2027 College Scholastic Ability Test.
LG Energy Solution’s 2027 College Scholastic Ability Test gift p…
Binggrae continued its growth momentum in the third quarter of this year, despite a decline in sales due to sluggish domestic demand, thanks to strong overseas operations and cost-cutting measures.Bin…
DaewonPharmaceutical(003220)Daewon Pharmaceutical is embarking on the development of a pediatric antipyretic based on “Felubi,” Korea’s 12th domestically developed new drug. This comes approximately 2…